Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of June 6, 2022, Yi Ching Yau, age 46, has been appointed Senior
Vice President, Finance and Principal Accounting Officer of ChemoCentryx, Inc.
(the "Company").
Prior to joining the Company, Ms. Yau served as the Chief Accounting Officer for
BridgeBio Pharma, Inc. from October 2019 to March 2022. Prior to BridgeBio
Pharma, Inc., Ms. Yau was Vice President, Finance at Nektar Therapeutics from
May 2018 to October 2019 and Corporate Controller and Assistant Treasurer at
Theravance Biopharma, Inc. from October 2013 to May 2018. From 2001 to 2013,
Ms. Yau worked at Ernst & Young LLP, most recently as Senior Manager, and is a
California Certified Public Accountant and Charted Accountant of Singapore. She
holds a Bachelor of Accountancy from Nanyang Technological University,
Singapore.
In connection with her commencement of employment, effective June 6, 2022, the
Compensation Committee of the Board of Directors of the Company approved the
grant of options to purchase 65,000 shares of the Company's common stock to
Ms. Yau. The stock options have an exercise price per share equal to $25.19, the
closing price of the Company's common stock on the Nasdaq Stock Market on
June 7, 2022, the grant date. The stock options will vest over a four-year
period, with 25% of the options vesting on the first anniversary of the date of
grant and the remainder of the options vesting monthly over the subsequent three
years, subject to Ms. Yau's ontinued service with the Company through the
applicable vesting dates. In addition, the stock options granted to Ms. Yau will
be subject to accelerated vesting as provided in the Company's change of control
policy. The stock options were granted under the Company's 2012 Equity Incentive
Plan and have a term of ten years from the grant date.
There are no arrangements or understandings between Ms. Yau and any other
persons pursuant to which she was selected as an officer, and there are no
related person transactions (within the meaning of Item 404(a) of Regulation
S-K) between Ms. Yau and the Company or family relationships between Ms. Yau and
any director or executive officer of the Company.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
CHEMOCENTRYX, INC. 
